Saturday, September 26, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Researchll-37cathelicidinapoptosiscancer

Review maps LL-37's dual proapoptotic and prosurvival signaling roles

Authors say the cathelicidin's effect on programmed cell death flips with cell type and peptide concentration, complicating therapeutic use.

PR
By Priya Raman · Science Reporter

The wire

  1. 01A review in the International Journal of Molecular Sciences summarizes how human cathelicidin LL-37 modulates apoptosis, with effects varying by cell type and peptide concentration, and covers LL-37 derivatives.
  2. 02LL-37 is tracked by readers as an immune peptide; the review underlines that direction of effect is context-dependent rather than uniformly protective.
  3. 03This is a narrative review, not new experimental data. The authors frame mechanistic understanding as a prerequisite for therapeutic application, including in cancer.

From the source

Apoptosis Modulation by LL-37: From Mitochondrial Cell Death to Prosurvival Signaling

International journal of molecular sciences · 2026 Sep 19 · Voronko OE, Novikova VS, Klychkova OO et al.

Read at pubmed.ncbi.nlm.nih.gov
PeptiPrescribed peptides from $99/moSee all →